Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study

IMR OpenIR

	Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study
其他题名	Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study
	Huang Qi 1; Sun Xuefeng 1; Lin Hongli 2; Zhang Zhimin 3; Hao Lirong 4; Yao Li 5; Li Jijun 6; Zhao Delong 1; Wang Yong 1; Zhu Hanyu 1; Chen Xiangmei 1
	2014
发表期刊	CHINESE MEDICAL JOURNAL
ISSN	0366-6999
卷号	127 期号:16 页码:2881-2887
摘要	Background Anticoagulation treatments are an important aspect of hemodialysis; however, few reports have addressed these treatments. This investigation intends to increase the understanding of the current status and improvements of hemodialysis-related anticoagulation treatments in China.
其他摘要	Background Anticoagulation treatments are an important aspect of hemodialysis; however, few reports have addressed these treatments. This investigation intends to increase the understanding of the current status and improvements of hemodialysis-related anticoagulation treatments in China. Methods In this study, an epidemiological investigation was conducted that examined 842 patients in 2007 and 1 175 patients in 2012 who underwent hemodialysis anticoagulation treatments in seven blood purification centers in northern Chinese cities. Results Heparin was the most commonly used anticoagulant, although the percentage of use of low-molecular-weight heparin (LMWH) increased from 26.5% in 2007 to 42.1% in 2012. In 2007, there were no significant differences in anticoagulant selection among either patients with various primary diseases or patients with hemorrhage, thrombosis, thrombocytopenia, or a low hemoglobin level. However, compared with patients with other diseases, significantly lower doses of LMWH were administered to patients with hypertension (55.5 U/kg vs. 67.3 U/kg, P <0.05) or diabetes (58.5 U/kg vs. 67.3 U/kg, P <0.05), and patients with hemorrhage received lower doses of heparin than the other patients (61.6 U/kg vs. 71.8 U/kg, P <0.01). In 2012, patients with diabetic nephropathy (51.5% vs. 36.5%, P <0.01), hemorrhage (43.4% vs. 31.7%, P <0.01), or a hemoglobin level below 90 g/L (57.2% vs. 37.1%, P <0.01) experienced significantly higher doses of LMWH administration; patients with hemorrhage received significantly reduced LMWH dosages (50.4 U/kg vs. 57.8 U/kg, P <0.05), and patients with thrombosis received significantly higher doses of heparin (73.8 U/kg vs. 62.1 U/kg, P <0.01) or LMWH (57.8 U/kg vs. 52.6 U/kg, P <0.05). Antiplatelet drugs were administered to 20.4% of the examined patients in 2007 and 20.7% in 2012. In 2012, patients with hypertension (25.9% vs. 18.5%, P <0.01) and thrombosis (36.6% vs. 16.1%, P <0.01) had a higher rate of using antiplatelet drugs than patients with other primary diseases and complications. Patients receiving antiplatelet drugs also received higher doses of heparin than patients without using antiplatelet drugs (74.4 U/kg vs. 65.9 U/kg, P <0.01). However, the use of the drugs was not correlated with thrombocytopenia. The rate at which coagulation indices were determined increased from 45.7% in 2007 to 64% in 2012. Conclusion These findings suggested that hemodialysis-related anticoagulation treatments in China have gradually become more standardized and individualized.
关键词	HEPARIN ASPIRIN DISEASE DOPPS hemodialysis heparin low-molecular-weight heparin anticoagulant
收录类别	CSCD
语种	英语
资助项目	[Major State Basic Research Development Program of China] ; [National Natural Science Foundation of China] ; [National Key Technology RD Program] ; [Health Industry Scientific Research Special Project]
CSCD记录号	CSCD:5214081
引用统计
文献类型	期刊论文
条目标识符	http://ir.imr.ac.cn/handle/321006/151323
专题	中国科学院金属研究所
作者单位	1.中国人民解放军总医院 2.First Affiliated Hosp, Dalian Med Coll, Department Nephrol, Dalian 116023, Liaoning, Peoples R China 3.Gen Hosp Gen Headquarters, Department Nephrol, Beijing 100091, Peoples R China 4.First Affiliated Hosp, Harbin Med Coll, Department Nephrol, Harbin 150081, Heilongjiang, Peoples R China 5.中国科学院金属研究所 6.Gen Hosp Peoples Liberat Army, Affiliated Hosp 1, Department Nephrol, Beijing 100048, Peoples R China
推荐引用方式 GB/T 7714	Huang Qi,Sun Xuefeng,Lin Hongli,et al. Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study[J]. CHINESE MEDICAL JOURNAL,2014,127(16):2881-2887.
APA	Huang Qi.,Sun Xuefeng.,Lin Hongli.,Zhang Zhimin.,Hao Lirong.,...&Chen Xiangmei.(2014).Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study.CHINESE MEDICAL JOURNAL,127(16),2881-2887.
MLA	Huang Qi,et al."Current status of anticoagulant treatments and improvements for hemodialysis patients in northern Chinese cities: a five-year comparative study".CHINESE MEDICAL JOURNAL 127.16(2014):2881-2887.